Skip to content
Triangle logo TriangleGet started
← Study library

NCT01885689 · REGISTRY CONDITION SEARCH

Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
ACTIVE NOT RECRUITING
Registry last update
2026-08-27

This phase II trial studies how well clofarabine and melphalan before a donor stem cell transplant works in treating patients with a decrease in or disappearance of signs and symptoms of myelodysplasia or acute leukemia (disease is in remission), or chronic myelomonocytic leukemia. Giving chemotherapy, such as clofarabine and melphalan, before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into a patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Giving clofarabine and melphalan before transplant may help prevent the cancer from coming back after transplant, and they may cause fewer side effects than standard treatment.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Progression-free Survival at 2 Years

→

outcome · POSTED

Overall Survival at 2 Years

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Patients in 1st or 2nd remission with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL), who are eligible for stem cell transplant. Remission defined as no circulating blasts, \< 5% blasts in the bone marrow, normalization of previously detected cytogenetic abnormalities, no extramedullary disease * High risk myelodysplastic syndrome (MDS) * Intermediate II and high risk by International Prognostic Scoring System (IPSS) * Intermediate, high, or very high by World Health Organization (WHO) classification-based Prognostic Scoring System (WPSS) * Transfusion dependent * Therapy-related MDS or MDS evolved from previous hematological disorder (excepting myelofibrosis) * Patients with chronic myelomonocytic leukemia (CMML) are allowed to be enrolled * Patients with MDS that has evolved to AML must be in remission * Patients must not be eligible for full ablative regimens by the attending physician * Patients with AML or MDS arising from myeloproliferative neoplasm can be enrolled after principal investigator (PI) approval on case to case basis, depends on the spleen size and degree of bone marrow fibrosis * Performance status of \>= 70% on the Karnofsky scale * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect she is pregnant while participating on the trial, she should inform her treating physician immediately * Bone marrow and peripheral blood studies must be available for confirmation of diagnosis; cytogenetics, flow cytometry, and molecular studies (such as Flt-3 status) will be obtained as per standard practice * Bone marrow aspirates/biopsies should be performed within 28 (+ 4 day window) days from registration to confirm disease remission status * A pretreatment measured creatinine clearance (absolute value) of \>= 60 mL/minute * Patients must have a serum bilirubin =\< 2.0 mg/dl * Patients must have serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) =\< 2.5 times the institutional upper limit of normal * Ejection fraction measured by echocardiogram or multi gated acquisition scan (MUGA) \> 50% * Diffusing capacity of the lung for carbon monoxide (DLCO) or forced expiratory volume in 1 second (FEV1) \> 45% predicted * Availability of a human leukocyte antigen (HLA) matched (6/6) sibling donor or 8/8 matched unrelated donor; Donors with mismatch at HLA-A, HLA-B, HLA-C, and HLA-DR will be reviewed by matched unrelated donor (MUD) committee and allowed if their mismatch with the recipient does not require additional GVHD prophylaxis (other than tacrolimus and sirolimus), donors with mismatch at HLA-DQ or HLA-DPB are eligible; donor evaluation according to City of Hope (COH) standard operating procedure (SOP) * Donor stem cell source can be either peripheral blood or bone marrow * All patients must have a psychosocial evaluation prior to transplant as per COH SOP * All subjects must have the ability to understand and the willingness to sign a written informed consent * ALL or AML patients who received chemotherapy (induction or consolidation) can proceed to transplant once bone marrow cellularity is \> 10 % with no evidence of leukemia Exclusion Criteria: * Patients who have received a prior autologous or allogeneic transplant are excluded * Patients with significant hepatic dysfunction (not meeting liver function tests \[LFT\] eligibility criteria) * Patients with MDS evolved into AML that is not in remission * Patients with acute promyelocytic leukemia * Patients with myeloproliferative neoplasms * Patients with suspected or proven central nervous system (CNS) leukemia; (diagnostic lumbar puncture not required before enrollment) * Uncontrolled intercurrent illness including, but not limited to ongoing or active or poorly controlled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, poorly controlled pulmonary disease or psychiatric illness/social situations that would limit compliance with study requirements * Pregnant and lactating women are excluded from this study * Patients who do not agree to practice effective forms of contraception * Human immunodeficiency virus (HIV)-positive patients are excluded from this study * Patients are excluded if they are hepatitis B surface antigen (sAg), hepatitis B (Hep B) core antibody (cAb), or hepatitis C (Hep C) positive. Patients with Hepatitis B cAB positive and Hepatitis B PCR negative are eligible if they started prophylactic treatment prior to registration to trial * Patients who have received radiation therapy as part of their leukemia treatment may be ineligible and individual cases must be presented to the study principal investigator (PI) for determination of eligibility * Any psychiatric, social or compliance issues that, in the treating physician's opinion, will interfere with completion of the transplant treatment and follow up * Medical or psychiatric reasons which make the donor unlikely to tolerate or cooperate with filgrastim (G-CSF) therapy or leukapheresis or bone marrow harvest * Known allergies to clofarabine, melphalan, sirolimus or tacrolimus * Patients with other active malignancies (besides AML, ALL, MDS) requiring treatment or where there is concern of progression are ineligible for this study; however, patients with previously treated skin cancer, early stage cervical or prostate cancer may be eligible if there is no evidence of residual disease * Cord blood as a donor source is not acceptable * Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study
healthy Volunteers
false
maximum Age
75 Years
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    CONDITIONING REGIMEN: Patients receive clofarabine IV over 2 hours on days -9 to -5 and melphalan IV over 30 minutes on day -4. TRANSPLANT: Patients undergo allogeneic hematopoietic stem cell transplant on day 0. GVHD PROPHYLAXIS: Beginning on day -3, patients receive tacrolimus IV or PO and sirolimus PO once daily with taper per City of Hope standard operating procedure.
    intervention Names
    1. Drug: clofarabine
    2. Drug: melphalan
    3. Procedure: allogeneic hematopoietic stem cell transplantation
    4. Drug: tacrolimus
    5. Drug: sirolimus
    6. Other: Pharmacological Study
    label
    Treatment (clofarabine, melphalan, transplant)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Treatment (clofarabine, melphalan, transplant)
    description
    Given IV
    name
    clofarabine
    other Names
    1. CAFdA
    2. Clofarex
    3. Clolar
    type
    DRUG
  2. arm Group Labels
    1. Treatment (clofarabine, melphalan, transplant)
    description
    Given IV
    name
    melphalan
    other Names
    1. Alkeran
    2. CB-3025
    3. L-PAM
    4. L-phenylalanine mustard
    5. L-Sarcolysin
    type
    DRUG
  3. arm Group Labels
    1. Treatment (clofarabine, melphalan, transplant)
    description
    Undergo allogeneic hematopoietic stem cell transplant
    name
    allogeneic hematopoietic stem cell transplantation
    type
    PROCEDURE
  4. arm Group Labels
    1. Treatment (clofarabine, melphalan, transplant)
    description
    Given IV or PO
    name
    tacrolimus
    other Names
    1. FK 506
    2. Prograf
    type
    DRUG
  5. arm Group Labels
    1. Treatment (clofarabine, melphalan, transplant)
    description
    Given PO
    name
    sirolimus
    other Names
    1. AY 22989
    2. Rapamune
    3. rapamycin
    4. SLM
    type
    DRUG
  6. arm Group Labels
    1. Treatment (clofarabine, melphalan, transplant)
    description
    Correlative studies
    name
    Pharmacological Study
    type
    OTHER
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
72
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Progression-free survival (PFS) is defined as time from start of protocol treatment to disease relapse/progression, death or last contact, whichever occurs first. Progression-free survival was estimated using the Kaplan-Meier method; the 95% confidence interval was calculated using Greenwood's formula.
    measure
    Progression-free Survival at 2 Years
    time Frame
    From start of protocol treatment to death due to any cause, disease relapse/progression, or last follow-up, whichever comes first, assessed up to 2 years.
secondary Outcomes
  1. description
    Overall survival (OS) is defined as time from start of protocol treatment to death from any cause. It was estimated using the Kaplan-Meier method; the 95% confidence interval was calculated using Greenwood's formula.
    measure
    Overall Survival at 2 Years
    time Frame
    From start of protocol treatment to death due to any cause, or last follow-up, whichever comes first, assessed up to 2 years.
Full study description
brief Summary
This phase II trial studies how well clofarabine and melphalan before a donor stem cell transplant works in treating patients with a decrease in or disappearance of signs and symptoms of myelodysplasia or acute leukemia (disease is in remission), or chronic myelomonocytic leukemia. Giving chemotherapy, such as clofarabine and melphalan, before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into a patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Giving clofarabine and melphalan before transplant may help prevent the cancer from coming back after transplant, and they may cause fewer side effects than standard treatment.
detailed Description
PRIMARY OBJECTIVES: I. Following a patient safety lead-in, determine the anti-tumor activity of clofarabine given in combination with high-dose melphalan as assessed by 2-year progression-free survival (PFS). II. Estimate overall survival (OS), cumulative incidence (CI) of relapse/progression and non-relapse mortality (NRM) at 100 days, 1 year and 2 years. III. Summarize toxicities/complications by organ and severity, including acute and chronic graft-vs-host disease (GVHD), and infection. OUTLINE: CONDITIONING REGIMEN: Patients receive clofarabine intravenously (IV) over 2 hours on days -9 to -5 and melphalan IV over 30 minutes on day -4. TRANSPLANT: Patients undergo allogeneic hematopoietic stem cell transplant on day 0. GVHD PROPHYLAXIS: Beginning on day -3, patients receive tacrolimus IV or orally (PO) and sirolimus PO once daily with taper per City of Hope standard operating procedure. After completion of study treatment, patients are followed up once weekly for 60 days, at 100, and 180 days, at one year, and then yearly for up to 5 years.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-21bb63c802099a27bc0f
      requested nct id
      NCT01885689
      primary nct id
      NCT01885689
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      cddcd4e3a59550bc78924062a298c359d8f811413f73f4a4461963aecf3790d6
      payload sha256
      04b76407b6005c8c71c4b3239eb8e7f0ec6b0dfc1c97de31312edaa634ef9549
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-21bb63c802099a27bc0f
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01885689
      occurrences
      1. context exact
        NCT01885689
        end
        11
        exact text
        NCT01885689
        start
        0
      offset unit
      unicode_code_points
      query cond
      Juvenile Myelomonocytic Leukemia
      query disease state id
      ds-juvenile-myelomonocytic-leukemia
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-juvenile-myelomonocytic-leukemia-000.json
      source file sha256
      cddcd4e3a59550bc78924062a298c359d8f811413f73f4a4461963aecf3790d6
      source json pointer
      /studies/2/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      90ec1653ede1bfb56cdb44d7471fcbfc8234f11502e8444b9392b10fb5e81785

    Preserved source evidence · Not medical advice